Simotinib Hydrochloride

DRUG2 trials

Sponsors

Jiangsu Simcere Pharmaceutical Co., Ltd.

Conditions

HealthyNon-small Cell Lung Cancer

Phase 1

Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of Simotinib Hydrochloride in Healthy Subjects

CompletedNCT01469910

Jiangsu Simcere Pharmaceutical Co., Ltd.Healthy

Start: 2011-09-30End: 2012-06-30Updated: 2012-07-10

Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of Simotinib Hydrochloride in Patients With Advanced NSCLC

Jiangsu Simcere Pharmaceutical Co., Ltd.Non-small Cell Lung Cancer

Start: 2012-12-31End: 2015-12-31Target: 30Updated: 2015-04-09

Related Papers

<p>Safety, tolerability, and pharmacokinetics of simotinib, a novel specific EGFR tyrosine kinase inhibitor, in patients with advanced non-small cell lung cancer: results of a phase Ib trial</p>

Cancer Management and Research2019-05-017 citations

Phase ib study of safety, tolerability and pharmacokinetics of simotinib in patients with advanced non-small cell lung cancer.

Journal of Clinical Oncology2017-05-201 citations

Clinical pharmacokinetics of simotinib, an oral EGFR tyrosine kinase inhibitor,in patients with advanced NSCLC patients.

Journal of Clinical Oncology2015-05-201 citations